S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024

Globus Medical (GMED) Stock Price, News & Analysis

$53.04
+1.42 (+2.75%)
(As of 03/27/2024 ET)
Today's Range
$51.92
$53.26
50-Day Range
$51.15
$56.52
52-Week Range
$43.38
$62.88
Volume
874,390 shs
Average Volume
1.08 million shs
Market Capitalization
$7.18 billion
P/E Ratio
45.33
Dividend Yield
N/A
Price Target
$66.33

Globus Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
25.1% Upside
$66.33 Price Target
Short Interest
Bearish
4.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.65mentions of Globus Medical in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$550,574 Sold Last Quarter
Proj. Earnings Growth
21.93%
From $2.69 to $3.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

25th out of 939 stocks

Surgical & Medical Instruments Industry

1st out of 99 stocks

GMED stock logo

About Globus Medical Stock (NYSE:GMED)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

GMED Stock Price History

GMED Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Globus Medical (NYSE:GMED) Upgraded by BTIG Research to Buy
Stocks Rally on Strength in Technology Stocks
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
GMED Apr 2024 57.500 call
GMED Apr 2024 50.000 put
Globus Medical price target raised by $3 at Stifel, here's why
Globus Medical: Q4 Earnings Insights
Globus Medical Reports Fourth Quarter and Full Year 2023 Results
PRCT Mar 2024 60.000 call
Globus Medical Q4 2023 Earnings Preview
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
37957720
Employees
5,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$66.33
High Stock Price Target
$86.00
Low Stock Price Target
$53.00
Potential Upside/Downside
+25.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$122.87 million
Pretax Margin
10.55%

Debt

Sales & Book Value

Annual Sales
$1.02 billion
Cash Flow
$3.71 per share
Book Value
$29.32 per share

Miscellaneous

Free Float
102,477,000
Market Cap
$7.18 billion
Optionable
Optionable
Beta
1.09
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

GMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GMED shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price target for 2024?

9 brokerages have issued 1 year price targets for Globus Medical's stock. Their GMED share price targets range from $53.00 to $86.00. On average, they predict the company's stock price to reach $66.33 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2024?

Globus Medical's stock was trading at $53.29 at the beginning of 2024. Since then, GMED shares have decreased by 0.5% and is now trading at $53.04.
View the best growth stocks for 2024 here
.

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 5,780,000 shares, an increase of 8.6% from the January 31st total of 5,320,000 shares. Based on an average trading volume of 1,220,000 shares, the days-to-cover ratio is currently 4.7 days.
View Globus Medical's Short Interest
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) announced its earnings results on Tuesday, February, 20th. The medical device company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.01. The medical device company had revenue of $616.53 million for the quarter, compared to analysts' expectations of $608.21 million. Globus Medical had a trailing twelve-month return on equity of 8.82% and a net margin of 7.83%. The company's revenue was up 124.6% on a year-over-year basis. During the same quarter last year, the business earned $0.59 EPS.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of 2.680-2.700 for the period, compared to the consensus estimate of 2.690. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.18%), Vanguard Group Inc. (8.33%), Wellington Management Group LLP (2.15%), Dimensional Fund Advisors LP (1.32%), Norges Bank (1.30%) and GW&K Investment Management LLC (1.28%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Leslie V Norwalk.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GMED) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners